Aquestive Therapeutics (AQST) Issues Earnings Results

Aquestive Therapeutics (NASDAQ:AQST) issued its quarterly earnings results on Tuesday. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.15), Fidelity Earnings reports. The business had revenue of $13.27 million during the quarter, compared to analysts’ expectations of $14.75 million.

AQST opened at $17.91 on Thursday. Aquestive Therapeutics has a fifty-two week low of $13.61 and a fifty-two week high of $20.70.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Massachusetts Financial Services Co. MA bought a new stake in shares of Aquestive Therapeutics during the 3rd quarter worth $5,305,000. Wasatch Advisors Inc. bought a new stake in shares of Aquestive Therapeutics during the 3rd quarter worth $2,545,000. Finally, Engineers Gate Manager LP bought a new stake in shares of Aquestive Therapeutics during the 3rd quarter worth $464,000. 1.22% of the stock is owned by institutional investors and hedge funds.

A number of brokerages have issued reports on AQST. Wedbush began coverage on Aquestive Therapeutics in a research note on Wednesday, September 12th. They set an “outperform” rating and a $33.00 price target for the company. Royal Bank of Canada set a $24.00 price target on Aquestive Therapeutics and gave the company a “buy” rating in a research note on Wednesday. BMO Capital Markets started coverage on Aquestive Therapeutics in a research note on Monday, August 20th. They set an “outperform” rating for the company. Finally, JMP Securities started coverage on Aquestive Therapeutics in a research note on Monday, August 20th. They set an “outperform” rating and a $29.00 price objective for the company.

ILLEGAL ACTIVITY NOTICE: “Aquestive Therapeutics (AQST) Issues Earnings Results” was originally published by WKRB News and is owned by of WKRB News. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at https://www.wkrb13.com/2018/11/08/aquestive-therapeutics-aqst-issues-earnings-results.html.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. Its products are developed using its PharmFilm technology. The company's marketed products include Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron antagonist for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery.

Featured Story: Asset Allocation Models, Which is Right For You?

Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply